Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies

Clinical Cancer Research

Volumn 6, Issue 11, 2000, Pages 4209-4216

  Scheulen, Max E ^a   Hilger, Ralf A ^a   Oberhoff, Carsten ^a   Casper, Jochen ^b   Freund, Matthias ^b   Josten, Klaus M ^c   Bornhäuser, Martin ^d   Ehninger, Gerhard ^d   Berdel, Wolfgang E ^e   Baumgart, Joachim ^f   Harstrick, Andreas ^a   Bojko, Andreas ^a   Wolf, Hans Heinrich ^g   Schindler, Adolf E ^a   Seeber, Siegfried ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f MEDAC GMBH   (Germany)

^g MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CYTOTOXIC AGENT; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST; TREOSULFAN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; ERYTHEMA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TOXIC EPIDERMAL NECROLYSIS;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033748741     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Stereoisomere 1,4-Di-O-methansulfonyl-butan-1,2,3,4tetrole
2. Combination chemotherapy of ovarian carcinoma with cisplatinum and treosulfan: A Phase II study
3. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma
4. Treosulfan as an effective second-line therapy in ovarian cancer
5. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: Feasibility and toxicity
6. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro
7. Antitumor activity of treosulfan against human breast carcinomas
8. Antitumor activity of treosulfan in human lung carcinomas
9. Dihydroxybusulfan (NSC-39069) in chronic myelocytic leukemia and miscellaneous malignant neoplasms
10. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo
11. Clinical Phase II trial of intravenous treosulfan in patients with non-pretreated metastatic small-cell lung cancer
12. Combination chemotherapy for choroidal melanoma: Ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside
13. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: The role of bcl-2
14. Treosulfan as an alternative conditioning agent in bone marrow transplantation
15. Treosulfan and fludarabine conditioning for allogeneic blood stem cell transplantation
16. Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate: The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate
17. DNA interstrand crosslinking and sequence selectivity of dimethanesulfonates
18. Induction of chromosomal aberrations and mutations with isomeric forms of L-threitol-1,4-bismethanesulfonate in plant materials
19. Activity of L-threitol-1,4-bismethanesulfonate on barley chromosomes in relation to chemical transformation during treatment
20. DNA alkylation and interstrand cross-linking by treosulfan
21. Discrimination between genotoxicity and cytotoxicity in the pathogenesis of DNA doublestrand breaks: Assessment by pulsed-field gel electrophoresis in cultured human lung epithelial cells
22. A Phase I trial of gemcitabine and treosulfan (GeT) to overcome multidrug resistance in patients with advanced solid tumors
23. PT vs. PC (cisplatinum/treosulfan vs. Cisplatinum cyclophosphamide) in advanced ovarian carcinoma: A Phase III study
24. A Phase I dose escalation trial of intravenous treosulfan in refractory cancer
25. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors
26. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma
27. A Phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas
28. Cardiotoxicity associated with high-dose cyclophosphamide therapy
29. Phase I study of high-dose dimethylbusulfan followed by autologous bone marrow transplantation in patients with advanced malignancies
30. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
31. Phase I evaluation of high dose melphalan, DTIC and treosulfan (MDT) in previously treated metastatic breast and ovarian cancer
32. Dose-escalation of treosulfan in a high-dose-protocol: A classical alkylating agent new in high-dose combination chemotherapy
33. The pharmacokinetics of oral and iv treosulfan
34. High-dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma
35. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer
36. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients
37. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses
38. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results
39. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy
40. A Phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral-blood stem cell support in patients with advanced ovarian or breast carcinoma
41. Phase II study of 'dose-dense' high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer
42. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral-blood progenitor cells: A Phase I/II study in advanced ovarian cancer